24 HR canagliflozin 150 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet... — RxCUI 1810999
RxNorm drug concept · Semantic branded drug
RxCUI 1810999
Semantic branded drug · SBD
● Current RxNorm concept 8 FDA products
8 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1810999
Official name24 HR canagliflozin 150 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet [Invokamet]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asInvokamet (canagliflozin 150 MG / metformin hydrochloride 1000 MG) 24HR Extended Release Oral Tablet; Invokamet XR 150 MG / 1000 MG 24HR Extended Release Oral Tablet
FDA products mapped8
Package NDCs mapped8
Reported Medicaid activity (SDUD)2,694 prescriptions · 17 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Canagliflozin: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Invokana helps lower your blood sugar by making your kidneys pass extra glucose out in your urine rather than keeping it in your blood. On top of that, if you also have heart disea...
- What exactly is Invokana supposed to do for me if I have type 2 diabetes?
- This is a real risk worth knowing about. In large clinical trials, people taking Invokana had about twice the rate of lower limb amputations compared to those on placebo — most com...
- I heard Invokana can cause amputations. How worried should I be?
🕸️ Concept Web — How 24 HR canagliflozin 150 MG / metformin hydrochlo... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
24 HR canagliflozin 150 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet [Invokamet]
RxCUI 1810999 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 4
The active substance itself — no strength, form, or brand attached yet.
-
Canagliflozin
1373458IN -
Metformin
6809IN -
Canagliflozin / metformin
1545149MIN -
Metformin hydrochloride
235743PIN
-
Canagliflozin
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Invokamet
1545151BN
-
Invokamet
-
Dose forms 13
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Canagliflozin / metformin Extended Release Oral Tablet
1810996SCDF -
Canagliflozin / metformin hydrochloride Extended Release Oral Tablet
2646125SCDFP -
Canagliflozin / metformin Oral Product
1545146SCDG -
Canagliflozin / metformin Pill
1545147SCDG -
Canagliflozin / metformin hydrochloride Oral Product
2663420SCDGP -
Canagliflozin / metformin hydrochloride Pill
2659101SCDGP -
Canagliflozin / metformin Extended Release Oral Tablet [Invokamet]
1810998SBDF -
Canagliflozin / metformin hydrochloride Extended Release Oral Tablet [Invokamet]
2656115SBDFP - +5 more in this family
-
Canagliflozin / metformin Extended Release Oral Tablet
-
Clinical & branded drugs 4
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
24 HR canagliflozin 150 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet
1810997SCD -
Canagliflozin 150 MG
1545145SCDC -
Metformin hydrochloride 1000 MG
860995SCDC -
Canagliflozin 150 MG / metformin hydrochloride 1000 MG [Invokamet]
1545152SBDC
-
24 HR canagliflozin 150 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet
Showing up to 8 concepts per family — 17 of 22 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
24 HR canagliflozin 150 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet
SCD · 1810997 -
Canagliflozin 150 MG
SCDC · 1545145 -
Metformin hydrochloride 1000 MG
SCDC · 860995 -
Canagliflozin / metformin Extended Release Oral Tablet
SCDF · 1810996 -
Canagliflozin / metformin hydrochloride Extended Release Oral Tablet
SCDFP · 2646125 -
Canagliflozin / metformin Oral Product
SCDG · 1545146 -
Canagliflozin / metformin Pill
SCDG · 1545147 -
Canagliflozin / metformin hydrochloride Oral Product
SCDGP · 2663420 -
Canagliflozin / metformin hydrochloride Pill
SCDGP · 2659101
Brand-Name Concepts
-
Canagliflozin 150 MG / metformin hydrochloride 1000 MG [Invokamet]
SBDC · 1545152 -
Canagliflozin / metformin Extended Release Oral Tablet [Invokamet]
SBDF · 1810998 -
Canagliflozin / metformin hydrochloride Extended Release Oral Tablet [Invokamet]
SBDFP · 2656115 -
Invokamet Oral Product
SBDG · 1545154 -
Invokamet Pill
SBDG · 1545155 -
Invokamet
BN · 1545151
📦 FDA Products & Package NDCs
8 products · 8 package NDCs
8 package NDCs map to RxCUI 1810999 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 50458-0540-60 | 60 TABLET, FILM COATED in 1 BOTTLE (50458-540-60) | INVOKAMET | Janssen Pharmaceuticals, Inc. | 2014-08-08 |
| 50458-0541-60 | 60 TABLET, FILM COATED in 1 BOTTLE (50458-541-60) | INVOKAMET | Janssen Pharmaceuticals, Inc. | 2014-08-08 |
| 50458-0542-60 | 60 TABLET, FILM COATED in 1 BOTTLE (50458-542-60) | INVOKAMET | Janssen Pharmaceuticals, Inc. | 2014-08-08 |
| 50458-0543-60 | 60 TABLET, FILM COATED in 1 BOTTLE (50458-543-60) | INVOKAMET | Janssen Pharmaceuticals, Inc. | 2014-08-08 |
| 50458-0940-01 | 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (50458-... | INVOKAMET XR | Janssen Pharmaceuticals, Inc. | 2016-09-20 |
| 50458-0941-01 | 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (50458-... | INVOKAMET XR | Janssen Pharmaceuticals, Inc. | 2016-09-20 |
| 50458-0942-01 | 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (50458-... | INVOKAMET XR | Janssen Pharmaceuticals, Inc. | 2016-09-20 |
| 50458-0943-01 | 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (50458-... | INVOKAMET XR | Janssen Pharmaceuticals, Inc. | 2016-09-20 |
Observed labelers:
Janssen Pharmaceuticals, Inc. (8)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.